XENON PHARMACEUTICALS INC. Cash and Cash Equivalents
XENON PHARMACEUTICALS INC. (XENE) had Cash and Cash Equivalents of $119.53 million as of 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Balance Sheet › Assets › Assets, Current › Cash, Cash Equivalents, and Short-Term Investments
us-gaap:CashAndCashEquivalentsAtCarryingValue · last filed 2026-08-06
- 2026-06-30: Cash and Cash Equivalents, at Carrying Value $119.53M.
- 2026-03-31: Cash and Cash Equivalents, at Carrying Value $545.87M.
- 2025-12-31: Cash and Cash Equivalents, at Carrying Value $199.16M.
- 2025-09-30: Cash and Cash Equivalents, at Carrying Value $104.51M.
| Period end | Cash and Cash Equivalents, at Carrying Value |
|---|---|
| 2026-06-30 | $119.53M 10-Q · filed 2026-08-06 |
| 2026-03-31 | $545.87M 10-Q · filed 2026-05-07 |
| 2025-12-31 | $199.16M 10-Q · filed 2026-08-06 |
| 2025-09-30 | $104.51M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $135.38M 10-Q · filed 2025-08-11 |
| 2025-03-31 | $116.66M 10-Q · filed 2025-05-12 |
| 2024-12-31 | $142.71M 10-K · filed 2026-02-26 |
| 2024-09-30 | $87.62M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $136.73M 10-Q · filed 2024-08-08 |
| 2024-03-31 | $58.90M 10-Q · filed 2024-05-09 |
| 2023-12-31 | $148.64M 10-K · filed 2025-02-27 |
| 2023-09-30 | $99.57M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $64.55M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $69.51M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $57.24M 10-K · filed 2024-02-29 |
| 2022-09-30 | $103.49M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $369.99M 10-Q · filed 2022-08-09 |
| 2022-03-31 | $116.54M 10-Q · filed 2022-05-10 |
| 2021-12-31 | $175.69M 10-K · filed 2023-03-01 |
| 2021-09-30 | $87.81M 10-Q · filed 2021-11-10 |
| 2021-06-30 | $82.93M 10-Q · filed 2021-08-11 |
| 2021-03-31 | $87.98M 10-Q · filed 2021-05-11 |
| 2020-12-31 | $45.01M 10-K · filed 2022-03-01 |
| 2020-09-30 | $15.10M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $44.20M 10-Q · filed 2020-08-06 |
| 2020-03-31 | $60.51M 10-Q/A · filed 2020-05-26 |
| 2019-12-31 | $24.75M 10-K · filed 2021-03-01 |
| 2019-09-30 | $37.67M 10-Q · filed 2019-11-05 |
| 2019-06-30 | $37.08M 10-Q · filed 2019-08-06 |
| 2019-03-31 | $52.18M 10-Q · filed 2019-05-07 |
| 2018-12-31 | $67.75M 10-K · filed 2020-03-09 |
| 2018-09-30 | $87.96M 10-Q · filed 2018-11-06 |
| 2018-06-30 | $47.44M 10-Q · filed 2019-08-06 |
| 2018-03-31 | $17.20M 10-Q · filed 2019-05-07 |
| 2017-12-31 | $20.49M 10-Q · filed 2019-08-06 |
| 2017-09-30 | $14.69M 10-Q · filed 2018-11-06 |
| 2017-06-30 | $23.09M 10-Q · filed 2018-08-07 |
| 2017-03-31 | $20.16M 10-Q · filed 2018-05-08 |
| 2016-12-31 | $17.09M 10-K · filed 2019-03-06 |
| 2016-09-30 | $54.13M 10-Q · filed 2017-11-07 |
| 2016-06-30 | $35.21M 10-Q · filed 2017-08-03 |
| 2016-03-31 | $56.06M 10-Q · filed 2017-05-09 |
| 2015-12-31 | $58.65M 10-K · filed 2018-03-07 |
| 2015-09-30 | $65.47M 10-Q · filed 2016-11-03 |
| 2015-06-30 | $64.35M 10-Q · filed 2016-08-03 |
| 2015-03-31 | $65.92M 10-Q · filed 2016-05-10 |
| 2014-12-31 | $72.03M 10-K · filed 2018-03-07 |
| 2014-09-30 | $33.73M 10-Q · filed 2015-11-10 |
| 2014-06-30 | $35.09M 10-Q · filed 2015-08-13 |
| 2014-03-31 | $34.95M 10-Q/A · filed 2015-08-13 |
| 2013-12-31 | $37.95M 10-K · filed 2017-03-08 |
| 2013-09-30 | $43.61M 10-Q · filed 2014-12-15 |
| 2012-12-31 | $60.16M 10-K · filed 2016-03-08 |
| 2011-12-31 | $13.93M 10-K · filed 2015-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Organon & Co. (OGN) | United States | $3.603B | 17.03 |
| ACADIA PHARMACEUTICALS INC (ACAD) | United States | $3.823B | 11.45 |
| IDEAYA Biosciences, Inc. (IDYA) | United States | $3.540B | -20.52 |
| AbCellera Biologics Inc. (ABCL) | $3.879B | -14.59 | |
| Amylyx Pharmaceuticals, Inc. (AMLX) | United States | $3.361B | -13.15 |
| Enliven Therapeutics, Inc. (ELVN) | United States | $3.307B | -35.07 |
| Arcutis Biotherapeutics, Inc. (ARQT) | United States | $3.303B | 115.47 |
| Tango Therapeutics, Inc. (TNGX) | United States | $4.154B | -42.53 |
| Arcus Biosciences, Inc. (RCUS) | United States | $3.188B | -8.52 |
| Indivior Pharmaceuticals, Inc. (INDV) | $4.250B | 14.09 |